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ABSTRACT Botrocetin, originally called venom coagglutinin,
is a Bothrops factor that causes aggregation of blood platelets in
the presence of the von Willebrand component of the factor VIII
macromolecular complex. The complex consists of a series of mul-
timers with a molecular weight of about 1-20 x 106. Ristocetin,
another agent that causes platelet aggregation dependent on von
Willebrand factor, reacts with only the higher molecular weight
multimers. We report on the reactivity of botrocetin in relation to
the multimeric structure of the factor VIII complex. Several plas-
mas or plasma fractions with abnormal distribution of the multi-
meric sizes were examined, including variant von Willebrand dis-
ease type HA with lack of the higher molecular weight forms,
commercial antihemophilic factor concentrates with a preponder-
ance of lower molecular weight forms, cryoprecipitate-free plasma
containing mainly the smaller multimers, and a chromatographic
fraction of plasma containing only the highest molecular weight
polymers. Factor VIII-related antigen content was adjusted to 25-
100%. All of the preparations lacking the high molecular weight
forms caused prompt platelet aggregation with botrocetin, but none
of them caused aggregation in the ristocetin test made isochronal
with the botrocetin test. The very high molecular weight polymers
were equally effective with botrocetin and ristocetin. These find-
ings indicate that the Bothrops factor is reactive with a broad spec-
trum of high to low molecular weight forms of the factor VIII com-
plex, suggesting that bioassays of von Willebrand factor with
botrocetin should correlate better with immunoassays for factor
VIII-related antigen and could reflect better the full platelet-ag-
gregating function of the complex than do ristocetin determina-
tions.
A factor found in the venom of several snakes, mainly in the
Bothrops species, has been shown to be a unique "activator" of
the platelet aggregation reaction that is dependent on the von
Willebrand factor (vWF). vWF, named because of its absence
in the severe form of the inherited bleeding disorder "desig-
nated von Willebrand disease (vWD)," is part of the factor VIII
macromolecular complex. The complex possesses two types of
biological activities. One is the antihemophilic factor (AHF) or
coagulant factor VIII (factor VIII:C) activity which corrects the
bleeding defect in hemophilia A. The other type is vWF activ-
ities (factor VIIIR:vWF) which correct the platelet-related func-
tional defect in vWD. These two types of activities of the com-
plex can be measured immunologically and are designated as
the factor VIII coagulant antigen (factor VIII:CAg) and the factor
VIII-related antigen (factor VIIIR:Ag), respectively. The com-
plex in normal plasma consists of a series of macromolecular
polymers of molecular weights ranging from about 106 to 20 X
106.
The uniqueness of the venom factor, originally called "venom
coagglutinin (VCA)" and more recently called "botrocetin," is
that at present it is the only material that can be used to identify
and quantify the platelet-aggregating vWF regardless of its
mammalian source (1, 2). Both ristocetin, the other known type
of activator of vWF-dependent platelet aggregation, and bo-
trocetin can be used to measure vWF activity in human plasma
(3), but vWF in most mammalian plasmas is resistant to risto-
cetin (2, 4). Ristocetin is known to cause platelet aggregation
with only the larger polymers or multimers of the factor VIII
macromolecular complex (5-9). This has led to the concept that
the platelet-aggregating function of the complex resides pri-
marily in the high molecularweight multimers of factor VIIIR:Ag.
Thus, plasmas from certain of the variants of vWD, known as
type IIA (6, 7, 10-12) which lack the highest molecular weight
multimers, do not aggregate platelets with ristocetin yet have
nearly normal or higher than normal levels of factor VIIIR:Ag.
Furthermore, the supernatant plasma remaining after the re-
moval of cryoprecipitate contains mainly the lower molecular
weight multimers of factor VIIIR:Ag and does not aggregate
platelets in the presence of ristocetin (7, 10, 12, 13).
The above observations led us to study the reactivity of bo-
trocetin with a number of plasmas or plasma preparations with
an abnormal distribution of factor VIIIR:Ag multimers to de-
termine if the pattern of reactivity of botrocetin was restricted
to the high molecular weight multimers as with ristocetin or if
it reacted with a broader spectrum of the polymers of the factor
VIII complex. The factor VIII macromolecular preparations
studied contained either (i) a predominance of the lower mo-
lecular weight multimers with marked reduction or absence of
the higher molecular weight forms or (ii) only the highest mo-
lecular weight polymers with absence of the smaller multimeric
types. It was found that botrocetin induced platelet aggregation
with all of the preparations tested, including those that were
inactive with ristocetin. Thus, botrocetin is also unique in re-
spect to its platelet-aggregating ability with the whole spectrum
of factor VIIIR:Ag multimers.
MATERIALS AND METHODS
Materials. Ristocetin (Lundberg, Copenhagen) was dis-
solved in isotonic saline at the desired concentration. Botrocetin
was prepared from the venom of Bothropsjararaca as described
(1) and was assayed for potency in units per ml (14). One unit
of botrocetin is defined as that amount in 1 ml that causes ag-
gregation of lyophilized platelets in 14 sec in a standardized pro-
cedure (14). The stock solution of botrocetin (500 units/ml) was
diluted with imidazole-buffered saline. Lyophilized human
platelets (15) were made from a blood bank platelet concentrate
72 hr old (16) with fixation in paraformaldehyde (17). The rabbit
Abbreviations: vWF, von Willebrand factor; vWD, von Willebrand dis-
ease; AHF, antihemophilic factor; factor VIII:C, coagulant factor VIII;
factor VIIIR:Ag, factor VIII-related antigen; factor VIII:CAg, factor VIII
coagulant antigen.
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FIG. 1. Analysis of vWF activity by using isochronal platelet-ag-
gregation tests with botrocetin and with ristocetin. Equilibration was
obtained by adjusting the final concentration of botrocetin (12.5
units/ml) and ristocetin (0.5 mg/ml) to give an aggregation time of 8
sec with undiluted reference plasma.
antiserum to human factor VIIIR:Ag and its preparation have
been described (12). Cryosupernatant was cryoprecipitate-free
human plasma (16). Cryoprecipitate (16) was obtained from
American Red Cross Blood Services (Columbia, SC). Factor VIII
concentrate [antihemophilic factor (human), Hemofil, Hyland,
Costa Mesa, CA) was dissolved in 20 ml of distilled water and
then diluted with imidazole-buffered saline. Type IIA vWD
plasmas were from two subjects, V. N., a 26-year-old black fe-
male, and W.R., a 17-year-old black male (12). Human refer-
ence plasma was a pool of platelet-poor plasmas from six healthy
subjects, ages 20-30 years, who denied ingestion of drugs dur-
ing the two weeks preceding blood sampling.
Methods. Platelet-aggregating tests for vWF with ristocetin
and with botrocetin (VCA) have been described (2, 3). Both the
macroscopic tap-tube and the aggregometry methods were used.
For macroscopic testing of cryosupernate, platelets were sus-
pended in cryosupernate (3 vol) before addition of activator (1
vol). A modified Laurell method for determining factor VIIIR:Ag
was that described by Lamb et al (12), as was the two-dimen-
sional electrophoresis using 1% agarose gel.
RESULTS
Equilibration of Ristocetin and Botrocetin Testing of vWF.
The rate of platelet aggregation induced with either ristocetin
or botrocetin was used to measure the expression of vWF ac-
tivity. It is known that the rate of platelet aggregation is de-
pendent not only on the concentration of vWF in the test ma-
terial but also on the concentration of botrocetin or ristocetin
(3). The normal reference plasma by definition had 100% factor
VIIIR:Ag with a full range of multimer sizes and 100% vWF ac-
tivity. The concentrations of botrocetin and ristocetin were
standardized so that the rate of platelet aggregation was the same
with both activators and human reference plasma. An 8-sec ag-
gregation time was selected for each activator with undiluted
plasma. It will be noted in Fig. 1 that human reference plasma
serially diluted caused platelet aggregation at nearly the same
rate with the adjusted concentrations of ristocetin and botro-
cetin (Fig. 1). This permitted reliable assessment of the com-
parability of response of test samples having an abnormal dis-
tribution of factor VIIIR:Ag multimers.
Botrocetin Reactivity with Lower Molecular Weight Mul-
timeric Forms of Factor VIIIR:Ag. Table 1 lists the plasmas
and plasma fractions that were studied along with data from a
representative analysis of each the various test and control sam-
ples. Each test sample was adjusted, as needed, to a factor
VIIIR:Ag level in the range 25-100% and was compared with
normal human reference plasma. Data on the parameters of mi-
gration of VIIIR:Ag in two-dimensional crossed immunoelec-
trophoresis are given. The maximum lateral migration was com-
parable for all samples, both test and control. However, all of
the test samples showed the beginning of the immunoprecipitin
arc at a considerable interval (4.0-6.4 mm) from the well (these
intervals are indicated as gap distances). The location of the peak
of the arc in relation to the lateral migration was anodal to the
peak for normal plasma. These data indicate a decrease in the
highest molecular weight multimers and a predominance of
smaller forms in all of the test samples.
The plasma from the two patients with type llA vWD pre-
viously had been documented as lacking the higher molecular
weight multimers but with factor VIIIR:Ag levels in the range
160-470% (W.R.) and 44-61% (V.N.) (12). The plasmas from
both patients failed to induce platelet aggregation with risto-
cetin. On the other hand, aggregation was rapid with botro-
cetin, indicating that it is reactive with the lower molecular weight
multimers of factor VIIIR:Ag.
The commercial factor VIII concentrate of normal human
plasma lacked the highest molecular weight multimers (Table
1). After dilution of the reconstituted concentrate sufficiently
to give a factor VIIIR:Ag value equivalent to that of normal
plasma, the macroscopic ristocetin test was negative. Neverthe-
Table 1. Reactivities of lower molecular weight multimers of factor VIIIR:Ag with ristocetin and botrocetin
Multimeric
Two-dimensional crossed distribution of
Factor immunoelectrophoresis Macroscopic vWF factor VIIIR:Ag
Plasma or VIIIR:Ag, migration distance, mm test, sec Higher Lower
plasma fractions % Lateral Gap Peak Ristocetin Botrocetin Mr Mr
vWD plasmas, type HA:
Subject W.R. 43 15 4.6 8.6 Negative 14 - +
Subject V.N. 78 13.1 5.5 8.5 Negative 14 - +
Plasma fractions:
Factor Vm concentrate* 100 12.4 6.4 9.6 Negative 18 Trace +
Cryosupernatet 25 12.5 4.0 8.2 Negative 30 - +
Human reference plasma:
Undiluted 100 13.8 0 6.1 8 8 + +
Diluted 1:4 25 12.6 2.0 6.3 14 14 + +
* Sample for vWF test had 25% factor VIIIR:Ag.
t Sample for vWF test had 100% factor VIIIR:Ag.
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less, the diluted concentrate caused rapid aggregation of plate-
lets with botrocetin. Disparate results were also obtained with
the aggregometric method with botrocetin and ristocetin (Fig.
2). These data indicate that botrocetin is reactive with the lower
molecular weight multimers of factor VIIIR:Ag. The lack of a
sufficient concentration of higher molecular weight multimers
in this commercial concentrate appears to be responsible for the
negative ristocetin test because both the ristocetin and botro-
cetin tests were positive with the undiluted preparation which
had a factor VIIIR:Ag value > 1,000%.
The cryosupernatant plasma fraction was used as a source of
the lowest molecular weight multimers of VIIIR:Ag. The ris-
tocetin test was negative (Table 1). These plasma fractions caused
prompt vWF-dependent platelet aggregation with botrocetin.
This study indicates that botrocetin is reactive with the lowest
molecular weight multimers of the factor VIIIR:Ag.
Botrocetin Reactivity with Higher Molecular Weight Mul-
timeric Forms of Factor VIIIR:Ag. The source of the largest
multimers of factor VIIIR:Ag was the first eluting fractions of
cryoprecipitate in the void volume upon Sepharose 4B chro-
matography (Table 2). The first three fractions with activity
(fractions 34-36) were nearly equally active with ristocetin and
botrocetin. The protein content was low as judged by optical
density at 280 nm. These data indicate that botrocetin detects












FIG. 2. Aggregometric study of responses of factor VIII concen-
trate (---) with ristocetin and botrocetin, compared with responses of
normal reference plasma (-). Test mixtures: for ristocetin testing,
0.18 ml of 0.084M imidazole-buffered saline (pH 7.35), 0.1 ml of plasma
(1:4) or concentrate (25% factor VIIIR:Ag), 0.1 ml of lyophilized plate-
lets (800,000/mm3), and 0.02 ml of ristocetin (20 mg/ml); for botro-
cetin testing, 0.19 ml of buffer, 0.1 ml of plasma or concentrate, 0.1 ml
of platelets, and 0.01 ml of botrocetin (500 units/ml).
Table 2. Reactivity of vWF is similar with ristocetin and
botrocetin in chromatographic fractions containing
highest molecular weight multimers
Macroscopic vWF Factor
Fraction* Absorbance test, sec VIIIR:Ag,
no. at 280 nm Ristocetin Botrocetin %
32 0.0 60 60 Neg.
33 0.0 60 60 Neg.
34 0.005 34 28 Neg.
35 0.015 7.3 7.0 44
36 0.025 5.0 5.0 143
40-50 0.0625-0.075 4-6 4-6 181-194
* A 5.0-ml sample of cryoprecipitate was chromatographed on a Seph-
arose 4B (Pharmacia) column, 1.6 x 70 cm. Elution buffer was 0.05
M Tris-buffered saline containing 5 mM trisodium citrate (pH 7.35).
The collected sample was 0.8 ml per tube.
DISCUSSION
Botrocetin, originally called venom coagglutinin (1), was dis-
covered several years ago during a search for an "activator" of
the vWF-platelet reaction that did not have the limitations of
the only known activator at that time, ristocetin. Ristocetin is
a protein-precipitating reagent and thus can cause false-positive
reactions in aggregometric testing. Also, ristocetin is highly re-
strictive in its reaction with the plasma vWF: it induces little or
no platelet aggregation with most mammalian plasmas and is
unreactive with most species of platelets except for those of hu-
man origin (2, 4). Also, ristocetin has only limited reactivity with
human factor VIIIR:Ag, being restricted to the high molecular
weight multimers (5-9). This study was designed to examine the
reactivity of botrocetin with the full range of multimers of hu-
man factor VIIIR:Ag in causing platelet aggregation and to com-
pare the action of botrocetin with that of ristocetin.
The first set of experiments was designed to test the platelet-
aggregating effect of botrocetin with factor VIIIR:Ag prepara-
tions that were unreactive with ristocetin and were largely lack-
ing in the higher molecular weight forms. Three preparations
were tested: variant vWD type IIA plasma from two patients,
a high-purity commercial preparation of factor VIII (AHF), and
the supernatant plasma remaining after preparation of cryopre-
cipitate. To obtain comparability of response with the two "ac-
tivators," all preparations were adjusted to a factor VIIIR:Ag
level within the range 25-100% of normal reference plasma.
Also, the concentrations of ristocetin and botrocetin were ad-
justed in the macroscopic procedure for determining vWF so
that equivalent platelet aggregation times were obtained with
each reagent and normal reference plasma (Table 1). This latter
control procedure is believed to be needed because the rate of
platelet aggregation in such tests is dependent not only on the
amount of vWF but also on the amount of the activator (3).
Two-dimensional crossed immunoelectrophoresis demon-
strated the lack of the high molecular weight multimers in the
plasmas of two subjects with variant vWD. This is a confir-
mation of similar data on these two plasmas previously reported
(12). These plasmas were inactive in the ristocetin screening test
for vWF. Thus, they lacked the so-called ristocetin cofactor.
However, both plasmas caused prompt platelet aggregation
with botrocetin. These findings suggest that botrocetin testing
would be a valuable additional diagnostic procedure for de-
tecting type IIA vWD.
Although extremely rich in factor VIII:C activity, the com-
mercial factor VIII concentrate has a greatly reduced content of
the higher molecular weight multimers of factor VIIIR:Ag (Ta-
ble 1) (12, 18) and is relatively ineffective in correcting the pro-
longed bleeding time in severe vWD (19). When the concen-
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trate was sufficiently diluted, it caused no platelet aggregation
with ristocetin, a finding in keeping with the depletion of high
molecular weight multimers. Platelet aggregation was prompt
with botrocetin.
The last of the three preparations with depleted high mo-
lecular weight multimers of factor VIIIR:Ag was the cryosu-
pernatant harvested in the preparation of therapeutic cryopre-
cipitate concentrates of AHF (factor VIII:C). The smaller
molecular weight multimers mainly go into solution when fro-
zen plasma is thawed at 4TC, but only limited amounts of larger
molecular weight multimers are solubilized. The ristocetin test
was negative, as expected, but the botrocetin test resulted in
platelet aggregation. The above group of experiments dem-
onstrate that the lower molecular weight multimers of factor
VIIIR:Ag are capable of causing prompt platelet aggregation with
botrocetin.
The last experiment in this study was designed to test whether
botrocetin was reactive with the highest molecular weight mul-
timers of factor VIIIR:Ag, as is ristocetin. It has been demon-
strated by Sepharose column chromatography of cryoprecipi-
tate that the first eluates contain only the highest molecular weight
multimers (8, 20). We took advantage of this phenomenon and
tested the early elution fractions for platelet-aggregating vWF
with both ristocetin and botrocetin (Table 2). The fractions caused
prompt platelet aggregation with both reagents, and aggrega-
tion times were approximately the same in the two tests. In the
first fraction, the botrocetin-induced aggregation time was
somewhat shorter than that with ristocetin. Thus, it is con-
cluded that botrocetin is reactive with the highest molecular
weight multimers of factor VIIIR:Ag.
In spite of the heterogeneity of factor VIIIR:Ag in plasma and
plasma fractions as well as the lack of reactivity or the mass of
smaller macromolecules with ristocetin, botrocetin was found
to be effective with the full range of sizes of the factor VIIIR:Ag
multimers in inducing platelet aggregation. This implies that a
correlation between vWF bioassay values with botrocetin and
immunoelectrophoretic determination of factor VIIIR:Ag should
be better than is the case for ristocetin assays. "Ristocetin co-
factor" is a term frequently used for the high molecular weight
multimers of factor VIIIR:Ag that cause platelet aggregation with
ristocetin. If one wanted an analogous term for the multimers
that cause platelet aggregation with botrocetin it would be "bo-
trocetin cofactor." Botrocetin cofactor values could be a better
indicator of the total potential platelet-aggregating activity of
plasma vWF than are ristocetin cofactor values.
Note Added in Proof. Since this manuscript was submitted, Howard et
aL (21) have published data on variant vWD similar to those shown in
Table 1.
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